MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells

Zeng,Xiaoqi; Jiang,Shanshan; Ruan,Simin; Guo,Zhaoze; Guo,Jingyun; Liu,Minfeng; Ye,Changsheng; Dong,Jianyu

doi:10.3892/mmr.2021.12187

MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells

Authors:
- Xiaoqi Zeng
- Shanshan Jiang
- Simin Ruan
- Zhaoze Guo
- Jingyun Guo
- Minfeng Liu
- Changsheng Ye
- Jianyu Dong
View Affiliations

Affiliations: Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Institute of Hematological Research, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710000, P.R. China
Published online on: June 2, 2021 https://doi.org/10.3892/mmr.2021.12187
Article Number: 548
Copyright: © Zeng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple‑negative breast cancer (TNBC) is the most common type of cancer among females worldwide and is associated with poor prognosis. Poly ADP‑ribose polymerase‑1 (PARP1) inhibitors are effective against TNBC with mutations in the breast cancer type 1 susceptibility protein (BRCA1) and/or BRCA2 genes; however, the development of resistance to PARP1 inhibitors limits their use. Thus, identifying strategies to overcome this resistance is urgently required. The aim of the present study was to investigate the potential function and mechanism of small interfering (si)RNA‑MAPK4 (siMAPK4) in enhancing the efficacy of a PARP1 inhibitor and reducing the resistance. In the present study, data on the mRNA expression level of MAPK4 in normal breast tissues and TNBC tissues were obtained from The Cancer Genome Atlas database. The mRNA and protein expression levels of MAPK4 in normal breast cells and TNBC cells were analyzed using reverse transcription‑quantitative PCR and western blotting, respectively. The phosphorylated (p) histone H2AX (γH2AX) protein expression was assessed via immunofluorescence. Cell Counting Kit‑8, wound healing and TUNEL assays were used to determine the proliferative, migratory and apoptotic abilities of HCC1937 cells. MAPK4 was highly expressed in TNBC patient tissues and cell lines. Moreover, overexpression of MAPK4 could promote HCC1937 cell proliferation. Treatment of HCC1937 cells with the combination of siMAPK4 and a PARP1 inhibitor olaparib decreased their proliferation and migration and increased their apoptosis. The protein expression levels of the DNA repair‑related proteins p‑DNA‑dependent protein kinase catalytic subunit (DNA‑PK) and RAD51 recombinase (RAD51) were inhibited in the siMAPK4 and siMAPK4 + olaparib groups. However, the marker of a double‑stranded break γH2AX showed increased protein expression in the siMAPK4 + olaparib group. As MAPK4 could phosphorylate AKT at threonine 308 (AKTT308), the current study restored p‑AKT^T308 using a constitutively active AKT plasmid (AKT‑CA). p‑DNA‑PK and RAD51 showed high expression and γH2AX exhibited lower protein expression in the AKT‑CA group. The present findings suggested that siMAPK4 can enhance the sensitivity of TNBC cells to PARP1 inhibitors.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	World Health Organization (WHO), . Cancer. https://www.who.int/news-room/fact-sheets/detail/cancerMarch 3–2021
3	Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U and Harbeck N: Triple-negative breast cancer-current status and future directions. Ann Oncol. 20:1913–1927. 2009. View Article : Google Scholar : PubMed/NCBI
4	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010. View Article : Google Scholar : PubMed/NCBI
5	Vagia E, Mahalingam D and Cristofanilli M: The landscape of targeted therapies in TNBC. Cancers (Basel). 12:9162020. View Article : Google Scholar : PubMed/NCBI
6	Coulombe P and Meloche S: Atypical mitogen-activated protein kinases: Structure, regulation and functions. Biochim Biophys Acta. 1773:1376–1387. 2007. View Article : Google Scholar : PubMed/NCBI
7	Lee BD, Park JM, Lee YM, Moon ES, Jeong HJ, Chung YI and Rim HD: A pilot study for discovering candidate genes of chromosome 18q21 in methamphetamine abusers: Case-control association study. Clin Psychopharmacol Neurosci. 12:54–64. 2014. View Article : Google Scholar : PubMed/NCBI
8	Cancer Genome Atlas Research Network, ; Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome atlas pan-cancer analysis project. Nat Genet. 45:1113–1120. 2013. View Article : Google Scholar : PubMed/NCBI
9	Wang W, Shen T, Dong B, Creighton CJ, Meng Y, Zhou W, Shi Q, Zhou H, Zhang Y, Moore DD and Yang F: MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling. J Clin Invest. 129:1015–1029. 2019. View Article : Google Scholar : PubMed/NCBI
10	Feng Y, Zhang L, Wu J, Khadka B, Fang Z, Gu J, Tang B, Xiao R, Pan G and Liu J: CircRNA circ_0000190 inhibits the progression of multiple myeloma through modulating miR-767-5p/MAPK4 pathway. J Exp Clin Cancer Res. 38:542019. View Article : Google Scholar : PubMed/NCBI
11	He J, Huang Z, He M, Liao J, Zhang Q, Wang S, Xie L, Ouyang L, Koeffler HP, Yin D and Liu A: Circular RNA MAPK4 (circ-MAPK4) inhibits cell apoptosis via MAPK signaling pathway by sponging miR-125a-3p in gliomas. Mol Cancer. 19:172020. View Article : Google Scholar : PubMed/NCBI
12	Piscitello D, Varshney D, Lilla S, Vizioli MG, Reid C, Gorbunova V, Seluanov A, Gillespie DA and Adams PD: AKT overactivation can suppress DNA repair via p70S6 kinase-dependent downregulation of MRE11. Oncogene. 37:427–438. 2018. View Article : Google Scholar : PubMed/NCBI
13	Zhang Y, Xie C, Li A, Vizioli MG, Reid C, Gorbunova V, Seluanov A, Gillespie DA and Adams PD: PKI-587 enhances chemosensitivity of oxaliplatin in hepatocellular carcinoma through suppressing DNA damage repair pathway (NHEJ and HR) and PI3K/AKT/mTOR pathway. Am J Transl Res. 11:5134–5149. 2019.PubMed/NCBI
14	Ali R, Rakha EA, Madhusudan S and Bryant HE: DNA damage repair in breast cancer and its therapeutic implications. Pathology. 49:156–165. 2017. View Article : Google Scholar : PubMed/NCBI
15	Gallmeier E and Kern SE: Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition. Cancer Biol Ther. 4:703–706. 2005. View Article : Google Scholar : PubMed/NCBI
16	Kim G, Ison G, McKe AE, Zhang H, Tang S, Gwise T, Sridhara R, Lee E, Tzou A, Philip R, et al: FDA approval summary: Olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res. 21:4257–4261. 2015. View Article : Google Scholar : PubMed/NCBI
17	Balasubramaniam S, Beaver JA, Horton S, Fernandes LL, Tang S, Horne HN, Liu J, Liu C, Schrieber SJ, Yu J, et al: FDA approval summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer. Clin Cancer Res. 23:7165–7170. 2017. View Article : Google Scholar : PubMed/NCBI
18	Noordermeer SM and van Attikum H: PARP inhibitor resistance: A tug-of-war in BRCA-mutated cells. Trends Cell Biol. 29:820–834. 2019. View Article : Google Scholar : PubMed/NCBI
19	Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI
20	Lin H, Li N, He H, Ying Y, Sunkara S, Luo L, Lv N, Huang D and Luo Z: AMPK inhibits the stimulatory effects of TGF-β on Smad2/3 activity, cell migration, and epithelial-to-mesenchymal transition. Mol Pharmacol. 88:1062–1071. 2015. View Article : Google Scholar : PubMed/NCBI
21	Jiang S, Wang Y, Luo L, Shi F, Zou J, Lin H, Ying Y, Luo Y, Zhan Z, Liu P, et al: AMP-activated protein kinase regulates cancer cell growth and metabolism via nuclear and mitochondria events. J Cell Mol Med. 23:3951–3961. 2019. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Kwon KY, Jan JH, Kwon SY, Cho CH, Oh HK and Kim SP: Cadmium induced acute lung injury and TUNEL expression of apoptosis in respiratory cells. J Korean Med Sci. 18:655–662. 2003. View Article : Google Scholar : PubMed/NCBI
24	Lyons TG: Targeted therapies for triple-negative breast cancer. Curr Treat Options Oncol. 20:822019. View Article : Google Scholar : PubMed/NCBI
25	Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005. View Article : Google Scholar : PubMed/NCBI
26	Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E and Jankowska A: PARP inhibitors: Review of mechanisms of action and BRCA1/2 mutation targeting. Prz Menopauzalny. 15:215–219. 2016.PubMed/NCBI
27	Lee JM, Ledermann JA and Kohn EC: PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 25:32–40. 2014. View Article : Google Scholar : PubMed/NCBI
28	Ryu JM, Choi HJ, Kim I, Nam SJ, Kim SW, Yu J, Lee SK, Choi DH, Park YH, Kim JW, et al: Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea. Breast Cancer Res Treat. 173:385–395. 2019. View Article : Google Scholar : PubMed/NCBI
29	D'Andrea AD: Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair (Amst). 71:172–176. 2018. View Article : Google Scholar
30	Mak JPY, Ma HT and Poon RYC: Synergism between ATM and PARP1 inhibition involves DNA damage and abrogating the G2 DNA damage checkpoint. Mol Cancer Ther. 19:123–134. 2020. View Article : Google Scholar : PubMed/NCBI
31	Tian S, Lou L, Tian M, Lu G, Tian J and Chen X: MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer. J Exp Clin Cancer Res. 39:1432020. View Article : Google Scholar : PubMed/NCBI
32	Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet. 376:235–244. 2010. View Article : Google Scholar : PubMed/NCBI
33	Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet. 376:245–251. 2010. View Article : Google Scholar : PubMed/NCBI
34	Shen T, Wang W, Zhou W, Coleman I, Cai Q, Dong B, Ittmann MM, Creighton CJ, Bian Y, Meng Y, et al: MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT. J Clin Invest. 131:e1354652021. View Article : Google Scholar : PubMed/NCBI
35	Cho YS, Lee GY, Sajja HK, Qian W, Cao Z, He W, Karna P, Chen X, Mao H, Wang YA and Yang L: Targeted delivery of siRNA-generating DNA nanocassettes using multifunctional nanoparticles. Small. 9:1964–1973. 2013. View Article : Google Scholar : PubMed/NCBI